Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 30 vs CABERGOLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, infertility),Prolactin-secreting pituitary adenomas (microadenomas and macroadenomas)
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Extensively metabolized in the liver, primarily by hydrolysis and minor CYP3A4 involvement.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
40-42% bound to plasma proteins, primarily albumin.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Approximately 100-150 L/kg, indicating extensive tissue distribution; Vd is large (≥100 L/kg) due to high lipophilicity and tissue binding.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
Oral bioavailability is about 40-45% (range 30-60%) due to first-pass metabolism. No parenteral formulations are commonly used.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
No dosage adjustment recommended for mild to moderate renal impairment (Cr Cl >10 m L/min); avoid use in severe renal impairment (Cr Cl <10 m L/min) due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh class C) as elimination may be reduced.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Not FDA approved for pediatric use; limited data: 0.025-0.05 mg/kg once weekly, titrated cautiously based on prolactin levels; maximum 0.1 mg/kg weekly.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
No specific adjustment recommended; start at lower end of dosing range (0.25 mg twice weekly) due to potential for increased sensitivity and age-related decline in renal function.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Cabergoline is associated with an increased risk of cardiac valve regurgitation, especially at high doses used for Parkinson's disease. The risk appears lower at doses used for hyperprolactinemia, but caution is advised.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Cardiac valvulopathy: monitor with echocardiography before and during therapy,Pleural, pericardial, and retroperitoneal fibrosis,Postural hypotension,Impulse control disorders (e.g., pathological gambling, hypersexuality),Remission of prolactinomas may reduce pituitary function
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Hypersensitivity to cabergoline or ergot derivatives,Uncontrolled hypertension,History of cardiac valvular disease,Pregnancy: use only if clearly needed (category B)
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Avoid high-fat meals that may increase absorption variability. No specific food restrictions, but take consistently with meals to maintain stable levels. Grapefruit juice may theoretically increase cabergoline exposure (CYP3A4 inhibition); avoid excessive consumption.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasoconstriction may cause fetal hypoxia; use only if benefit outweighs risk. Second and third trimesters: risk of postpartum hemorrhage and uterine atony if used for lactation suppression; avoid in pregnancy due to potential for fetal harm from dopamine agonist effects.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Cabergoline suppresses lactation; contraindicated in breastfeeding women because it reduces milk production. If used, discontinue breastfeeding or avoid drug. M/P ratio not established; drug is excreted in rat milk, unknown in humans.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
No standard dose adjustment recommended; avoid use during pregnancy unless absolutely necessary (e.g., prolactinoma). Pregnancy may alter cabergoline pharmacokinetics (increased volume of distribution, decreased clearance) but specific dose modifications are not established. If used, monitor prolactin levels and clinical response.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Start with 0.25 mg twice weekly, titrate by 0.25 mg every 2-4 weeks based on prolactin levels and tolerability. Maximum dose typically 1 mg twice weekly. May cause orthostatic hypotension; caution when rising from supine position. Use lowest effective dose to minimize risk of valvulopathy, especially with cumulative doses >2 mg/day. Discontinue if signs of cardiac fibrosis. Monitor for impulse control disorders (e.g., hypersexuality, gambling). Avoid in patients with uncontrolled hypertension or pre-existing cardiac valvular disease.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
Take with food to reduce gastrointestinal upset.,Avoid alcohol as it may increase side effects like dizziness or nausea.,Rise slowly from sitting or lying positions to prevent fainting.,Report any new shortness of breath, swelling, or chest pain immediately.,Notify your doctor if you experience unusual urges (gambling, sex, spending).,Do not drive or operate machinery if you feel dizzy or drowsy.,Take exactly as prescribed; do not double the dose if missed.,Store at room temperature away from moisture and heat.
No interactions on record
"Trazodone, a serotonin antagonist and reuptake inhibitor, and cabergoline, a dopamine D2 receptor agonist, exhibit opposing effects on the dopaminergic and serotonergic systems, potentially leading to reduced therapeutic efficacy and increased risk of adverse effects such as serotonin syndrome or dopaminergic toxicity. The combination may precipitate hypertensive crises or cardiac valvulopathy due to additive effects on 5-HT2B receptor activation by cabergoline, while trazodone's blockade of serotonin reuptake can exacerbate serotonin excess. Clinical outcomes include unpredictable blood pressure fluctuations, neuropsychiatric disturbances, and rare but serious cardiovascular events."
"Cabergoline, a dopamine D2 receptor agonist used for hyperprolactinemia, may inhibit the metabolism of methylene blue, a monoamine oxidase inhibitor (MAOI) used for methemoglobinemia. This interaction can lead to elevated methylene blue levels, increasing the risk of serotonin syndrome, characterized by hyperthermia, agitation, and neuromuscular abnormalities. Clinically, patients may present with confusion, tachycardia, and hypertension, necessitating cautious use."
"Cabergoline, a dopaminergic ergot derivative, acts as a vasoconstrictor via agonism of serotonin 5-HT2B and dopamine D1 receptors in vascular smooth muscle. Nadolol, a non-selective beta-blocker, inhibits beta-2 adrenergic receptor-mediated vasodilation, leaving alpha-adrenergic vasoconstriction unopposed. The combined vasoconstrictive effects can lead to additive peripheral and coronary vasoconstriction, potentially causing severe hypertension, myocardial ischemia, or Raynaud's phenomenon."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 30 vs CABERGOLINE, answered by our medical review team.
ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. CABERGOLINE is a Dopamine Agonist that works by Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 30 and CABERGOLINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. The standard adult dose of CABERGOLINE is: 0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 30 and CABERGOLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. CABERGOLINE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasocon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.